SCHEMBL2302437

SCHEMBL2302437

O=C(O)c1ccc(N2CCNCC2)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
HPGD P15428 5/20 0.51
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
TSHR P16473 2/20 0.51
TP53 P04637 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
ALDH1A1 P00352 6/20 0.50
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GAA P10253 3/20 0.48
KDM4E B2RXH2 2/20 0.48
POLB P06746 2/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
LMNA P02545 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3085306 0.86 MAPT (0.51) MAPTHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL3921035 0.86 ALDH1A1 (0.60) MAPTHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL17195413 0.85 MAPT (0.68) MAPTHPGDRAB9ANPC1SMN1; SMN2
Piperazine SCHEMBL4934731 0.85 ALDH1A1 (0.59) MAPTHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL6125360 0.84 HPGD (0.68) MAPTHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL4939504 0.84 MAPT (0.48) MAPTHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL27950425 0.83 MYC (0.51) MAPTTSHRALDH1A1GAAKDM4E
SCHEMBL2307303 0.83 ADRB1 (0.50) TSHRALDH1A1KMT2AMEN1GAA
SCHEMBL531792 0.82 MAPT (0.50) MAPTHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL30542902 0.82 MAPT (0.50) MAPTHPGDRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP claimed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US claimed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 EP claimed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO claimed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 MAPT 4008/4885HPGD 951/4885RAB9A 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.